View Item 

Show simple item record

Vaccination against COVID- 19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders

dc.contributor.authorKaczmarek, Radoslaw
dc.contributor.authorEl Ekiaby, Magdy
dc.contributor.authorHart, Daniel P.
dc.contributor.authorHermans, Cedric
dc.contributor.authorMakris, Mike
dc.contributor.authorNoone, Declan
dc.contributor.authorO’mahony, Brian
dc.contributor.authorPage, David
dc.contributor.authorPeyvandi, Flora
dc.contributor.authorPipe, Steven W.
dc.contributor.authorSannié, Thomas
dc.contributor.authorSchlenkrich, Uwe
dc.contributor.authorSkinner, Mark W.
dc.contributor.authorSrivastava, Alok
dc.contributor.authorBok, Amanda
dc.contributor.authorPierce, Glenn F.
dc.date.accessioned2021-08-03T18:15:56Z
dc.date.available2022-08-03 14:15:55en
dc.date.available2021-08-03T18:15:56Z
dc.date.issued2021-07
dc.identifier.citationKaczmarek, Radoslaw; El Ekiaby, Magdy; Hart, Daniel P.; Hermans, Cedric; Makris, Mike; Noone, Declan; O’mahony, Brian ; Page, David; Peyvandi, Flora; Pipe, Steven W.; Sannié, Thomas ; Schlenkrich, Uwe; Skinner, Mark W.; Srivastava, Alok; Bok, Amanda; Pierce, Glenn F. (2021). "Vaccination against COVID- 19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders." Haemophilia (4): 515-518.
dc.identifier.issn1351-8216
dc.identifier.issn1365-2516
dc.identifier.urihttps://hdl.handle.net/2027.42/168487
dc.publisherBioNTech
dc.publisherWiley Periodicals, Inc.
dc.titleVaccination against COVID- 19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/168487/1/hae14271.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/168487/2/hae14271_am.pdf
dc.identifier.doi10.1111/hae.14271
dc.identifier.sourceHaemophilia
dc.identifier.citedreferenceChakraborty R, Parvez S. COVID- 19: an overview of the current pharmacological interventions, vaccines, and clinical trials. Biochem Pharmacol. 2020; 180: 114184.
dc.identifier.citedreferenceVerbeke R, Lentacker I, De Smedt SC, et al. Three decades of messenger RNA vaccine development. Nano Today. 2019; 28: 100766.
dc.identifier.citedreferenceVoysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV- 19 vaccine (AZD1222) against SARS- CoV- 2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet (London, England). 2020.
dc.identifier.citedreferencePipe SW, Kaczmarek R, Srivastava A, et al. Management of COVID- 19- associated coagulopathy in persons with haemophilia. Haemophilia. 2020.
dc.identifier.citedreferenceHermans C, Lambert C, Sogorb A, et al. In- hospital management of persons with haemophilia and COVID- 19: practical guidance. Haemophilia. 2020; 26 ( 5 ): 768 - 772.
dc.identifier.citedreferenceModerna- s COVID- 19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study | Moderna, Inc. https://investors.modernatx.com/news- releases/news- release- details/modernas- covid- 19- vaccine- candidate- meets- i
dc.identifier.citedreferencePolack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID- 19 vaccine. N Engl J Med. 2020;NEJMoa2034577.
dc.identifier.citedreferenceAnderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS- CoV- 2 mRNA- 1273 vaccine in older adults. N Engl J Med. 2020; 383: 2427 - 2438.
dc.identifier.citedreferenceConfirmation of guidance to vaccination centres on managing allergic reactions following COVID- 19 vaccination with the Pfizer/BioNTech vaccine. https://www.gov.uk/government/news/confirmation- of- guidance- to- vaccination- centres- on- managing- allergic- reactio
dc.identifier.citedreferenceLai JD, Moorehead PC, Sponagle K, et al. Concurrent influenza vaccination reduces anti- FVIII antibody responses in murine hemophilia A. Blood. 2016; 127 ( 26 ): 3439 - 3449.
dc.identifier.citedreferencePlatokouki H, Fischer K, Gouw SC, et al. Vaccinations are not associated with inhibitor development in boys with severe haemophilia A. Haemophilia. 2018; 24 ( 2 ): 283 - 290.
dc.identifier.citedreferenceGarvey LH, Nasser S. Allergic reactions to the first COVID- 19 vaccine: is polyethylene glycol (PEG) the culprit? Br J Anaesth. 2020.
dc.identifier.citedreferenceCOVID- 19 MRNA Vaccine BNT162b2 Concentrate for Solution for Injection [Package Insert]. Mainz, Germany: BioNTech; 2020.
dc.identifier.citedreferenceOliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices- Interim Recommendation for Use of Pfizer- BioNTech COVID- 19 Vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep. 2020; 69 ( 50 ): 1922.
dc.identifier.citedreferenceMASAC Document 221. Recommendations on Administration of Vaccines to Individuals with Bleeding Disorders | National Hemophilia Foundation. https://www.hemophilia.org/healthcare- professionals/guidelines- on- care/masac- documents/masac- document- 221- recommend
dc.identifier.citedreferenceSrivastava A, Brewer AK, Mauser- Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013; 19 ( 1 ): e1 - 47.
dc.identifier.citedreferenceSantagostino E, Riva A, Cesaro S, et al. Consensus statements on vaccination in patients with haemophilia- results from the Italian haemophilia and vaccinations (HEVA) project. Haemophilia. 2019; 25 ( 4 ): 656 - 667.
dc.identifier.citedreferenceSrivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia. Haemophilia. 2020; 26 ( S6 ): 1 - 158.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hae14271.pdf
Size:
346.1KB
Format:
PDF
View/Open
Name:
hae14271_am.pdf
Size:
184.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.